de Wilde 1985.

Methods	Six‐week controlled, double‐blind, randomised trial.
Participants	In‐patients suffering from endogenous depression or chronic dysthymic disorder (Spitzer's research Diagnostic Criteria), with a total score of at least 25 on the 10‐item Comprehensive Psychopathological Rating Scale (CPRS) sub‐scale for depression. Age range: 18‐70 years Exclusion criteria: pregnancy/lactation, serious somatic disease (particularly of the heart, liver or kidneys), organic brain syndrome, need for ECT, abuse of alcohol or drugs, and treatment with MAO inhibitors within the previous 3 weeks.
Interventions	Citalopram: 30 participants Mianserin: 30 participants Citalopram dose range: 40‐80 mg/die Mianserin dose range:60‐120 mg/die Additional medication with benzodiazepine as sedatives/hypnotics was permitted.
Outcomes	Primary outcome: mean change at endpoint on the 10‐item CPRS sub‐scale for depression and on Clinical Global Impression ‐ Severity (CGI‐S).
Notes	This study was funded by Lundbeck (citalopram manufacturer).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: " Patients were randomly allocated". Probably done.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "double blind treatment with either citalopram or mianserin, administered as identically looking capsules".
Incomplete outcome data (attrition bias) All outcomes	High risk	Observed‐case (completers) analysis only
Selective reporting (reporting bias)	High risk	No reliable data about response rate.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.